An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

Completed · Phase 1

Conditions studied: Neurofibromatosis 2

In brief

This is a study to gather some information on the safety and efficacy of the penetrating auditory brainstem implant (PABI) in patients with neurofibromatosis type 2.

Key facts

Study ID

NCT00030043

Run by

FDA Office of Orphan Products Development

People needed

10

Starts

2001-09-01

Expected to finish

2003-08-01

Last updated by the study team

2015-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of neurofibromatosis type 2
• Speak English as a primary language

You may not qualify if…

• Physical, psychological, or medical conditions that contraindicate the surgical procedure

Where it is running

• House Ear Institute — Los Angeles, California, United States
• Huntington Medical Research Institutes — Pasadena, California, United States
• Cochlear Corporation — Englewood, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.